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Abstract
Background: To compare the epidemiological and clinical features and outcome in clonal group O25b/ST131
and non-clonal group O25b/ST131 in adult patients with non-extended-spectrum B-lactamase (ESBL)-producing
Escherichia coli (E. coli) bacteraemia.
Methods: We collected 371 consecutive isolates with community-onset non-ESBL producing E. coli bloodstream
infection in 2010 in a 1200-bed hospital in Taiwan. Twenty adult patients with clonal group O25b/ST131 and 40
patients with non-clonal group O25b/ST131 were compared.
Result: Clonal group O25b/ST131 accounted for 5.9% of total isolates. The underlying disease and
healthcare-associated risk factors were similar in the case and control groups. Patients with the clonal group
O25b/ST131 were less likely to have intra-abdominal infection (0% vs. 22.5%; p < 0.05) than patients from the
control group. The Day 30 mortality rate was similar in the case and control groups (15% vs. 12.5%).
Conclusions: Clonal group O25b/ST131 was found in both multidrug-resistant and susceptible E. coli strains,
causing community-onset bloodstream infection. Although O25b/ST131 does not lead to a higher mortality than
other isolates, choosing an appropriate antimicrobials in the empirical therapy of community-onset E. coli
bacteraemia has become more challenging.
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Background
From 2000 to 2006, the Escherichia coli clone O25:H4-
ST131, which produces CTX-M-15 extended-spectrum B-
lactamase (ESBL), was identified in three continents [1-3].
ST131's distinctive combination of resistance and viru-
lence, as well as its widespread dissemination among the
locals, may underlie its epidemiologic success. Later stud-
ies have showed that clone ST131 exists in non-ESBL pro-
ducing fluoroquinolone-resistant E. coli isolates [4-8].
ST131 accounted for 25% to 78% of fluoroquinolone re-
sistant E. coli infection in the surveillance form in Asia
and the US [3-8]. In our previous studies, fluoroquinolone
(29%) and cefazolin (25%) resistant uropathogens were
common in adults with community-onset urinary tract in-
fections (UTI) in a teaching hospital in southern Taiwan.
[9] There were several risk factor to be independently as-
sociated with community onset UTI fluoroquinolone re-
sistant pathogens (i.e. recent hospitalization, underlying
old stroke, and diabetes mellitus) [9]. Although cephalo-
sporin and fluoroquinolone are the recommended anti-
microbials to use in community-onset complicated UTI
or bloodstream infection, the emergence of clone ST131
with fluoroquinolone resistance in acute pyelonephritis
poses a challenge in choosing the adequate antimicro-
bials. In our institution, we often used 3rd generation
cephalosporin such as ceftriaxone or fluoroquinolone
such as levofloxacin or ciprofloxacin as empirical antibi-
otics for community-onset complicated UTI or gram
negative bacillary bacteremia.
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Our previous studies compared the clinical features and
outcome in ST131 vs. non-ST131 in ESBL-producing
E. coli bacteremia [10]. We found that ST131 was associ-
ated with non-catheter related UTI (urinary tract infec-
tion) and that it is not associated with higher mortality [10].
According to our review of the literature, we did not find
clinical data for clone ST131 in community-onset ESBL-
negative E. coli bacteremia. To further understand the role
of ST131 in community-onset non-ESBL-producing E. coli
bacteremia, we collected non-duplicated consecutive E. coli
bloodstream infection isolates in 2010 in a medical center in
southern Taiwan. Our goals were to determine the percent-
age of ST131 in community-onset non-ESBL-producing
E. coli bloodstream infection and to find out if patients with
ST131 clone have clinical features or outcome different
from patients with a non-ST131 clone.
Method
Study design, setting and participants
The study was done retrospectively and included patients
older than 16 years old with at least one positive blood
culture of ESBL-negative E. coli who were admitted to the
E-Da Hospital during a one-year period as Figure 1 (from
Jan 1, 2010 to Dec 31, 2010). E-Da Hospital is a 1200-bed
major teaching hospital in southern Taiwan that pro-
vides both primary and tertiary medical care. Only
strains from the first bacteremic episode were included
in the analysis. Blood cultures were processed using the
automated blood culture system. (BD Phoenix™ Auto-
mated Microbiology System)
In the present study, non-susceptibility arbitrarily re-
fers to the category of intermediate and resistant results,
obtained using the MIC (minimal inhibitory concentration)
value in accordance with the criteria from the Clinical and
Laboratory Standards Institute, M100-S21.
Variables, collection of data and definitions
All patients were evaluated using a standard case re-
cording form. Each clinical course of infection was eval-
uated and recorded according to the information
supplied by primary care physicians and medical records
reviewing retrospectively. The diagnosis of infection focus
of bacteremia was based on clinical, bacteriological, and
radiological investigations.
The following items were recorded for each patient:
age; sex; underlying illness; infection syndrome type;
Figure 1 Algorism of methods and cases analyses.
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history of hospitalization within the previous three months;
antimicrobials exposure within the previous three months,
existence of a urinary catheter; initial empirical antimicro-
bial agents; and outcome. If an in vitro active antimicro-
bial agent was not administered before the final result
of blood culture, the procedure was considered a dis-
cordant empirical therapy.
This study was supported by the E-Da Hospital Research
Committee and approved by the institutional review board
of E-Da Hospital. (EDAH IRB No./Protocol No: EMRP-
102-048). Because the study was done via medical chart
reviewing retrospectively and the pathogens were col-
lected from the stock of the infectious isolates from the la-
boratory. The IRB waived informed consent requirements
due to the research involves no more than minimal risk to
the subjects and the waiver will not affect adversely the
rights and welfare of the patients.
Microbiological studies
O25 positve E. coli isolates were determined by the PCR
method described by Clermont et al [2]. All O25b posi-
tive E. coli isolates were characterized by multilocus
sequence typing (MLST) using the standard seven house-
keeping genes (adk, fumC, gyrB, icd, mdh, purA, and
recA), according to the protocol and primers specified by
the E. coli MLST web site (http://mlst.warwick.ac.uk/mlst/
dbs/Ecoli) [2,11] MLST was also performed on a randomly
selected subset of 40 O25b negative E-coli isolates. Clonal
relationships were established by pulsed-field gel electro-
phoresis (PFGE) of XbaI-digested genomic DNA. To com-
pare the band patterns of aggregated data, the GelCompar
software package (version 6.0; Applied Maths, Bionumerics)
was used. Strains showing 80% or greater banding pattern
similarity were considered to have similar or identical
electrokaryotypes.
Statistical analysis
Descriptive statistics, including means, standard devia-
tions, and ranges, were used to analyze continuous vari-
ables, whereas percentages and confidence intervals were
used to analyze categorical variables. Independent-t test
was used for continuous variables. A Chi-square test or
Fisher’s exact test was used for categorical variables. The
variables in bivariate analyses with a p value <0.1 were in-
cluded in a multivariate analysis, which was performed
using a logistic regression model to identify factors that in-
dependently and significantly affected the outcome. A
p value <0.05 was considered to be statistically significant.
All statistical analyses were done using SPSS 15 for
Windows, Chicago, IL, USA.
Result
Of the 371 non-duplicated consecutive E. coli bloodstream
infection isolates, 43.9%, 30.7%, 15.4%, 15.4%, 13.2%, and
4.6% were resistant to trimethoprim/sulfamethoxazole
(TMP/SMZ), amoxicillin/clavunate, cefazolin, gentamicin,
ciprofloxacin, and cefotaxime, respectively (data not
shown). The antibiotic resistance of all 371 isolates of clonal
group O25b/ST131 and non clonal group O25b/ST131
were shown in the Additional file 1: Table S1. Clonal group
131 were more likely to have TMP/SMZ, ciprofloxacin, cef-
metazole, and gentimicin resistance (P < 0.05). Clonal group
O25b/ST131 (n = 22) accounted for 5.9% of the total iso-
lates. Two cases of O25-ST131 did not have a complete
history in our hospital and were excluded from further
clinical analysis.
We collected clinical data from the remaining 20 cases
of clonal group O25b/ST131 and 40 randomly selected
cases of non-O25b/ST131 genotypes, which were used
as controls. The most predominant ST types in the 40
non-O25b/ST131 isolates included ST95 (n = 12) and ST
69 (n = 6). The underlying co-morbidity and healthcare-
associated risk factors (such as hospitalization and anti-
microbials use) were similar in the case and control
groups, as shown in Table 1. Patients with clonal group
O25b/ST131 were less likely to have intra-abdominal in-
fection (0% vs. 22.5%; p < 0.05) than patients with non-
O25b/ST131 clones. Nine cases (15%) received discordant
antimicrobials before susceptibility data were available in-
cluded levofloxacin (n = 4), cephazolin (n = 2), ceftriaxone
(n = 1), cefuroxime (n = 1) and amoxicillin/clavunate
(n = 1). There were 20% patients in clonal group O25b/
ST131 and 12.5% in non-clonal group O25b/ST131
that received discordant antimicrobials before suscep-
tibility data were available (p = 0.464).
The Day 30 mortality rate was similar in the clonal
group O25b/ST131 and non-clonal group O25b/ST131
(12.5% vs. 15%, p = 1.00), but patients infected with the
clonal group O25b/ST131 were more likely to have ESBL
E. coli infection in the following two years than patients
infected with the non-ST131 group (20% vs. 2.5% p < 0.05)
(data not shown). However, we don’t have the following
ESBL E. coli isolates for further pulsotype study. The uni-
variate risk factors for Day 30 mortality included under-
lying chronic renal failure (OR: 5.6; 95% CI: 3.0-31.0; p =
0.046) and solid organ cancer (OR: 7.0; 95% CI: 1.4 -34.2;
p = 0.016). The only independent risk factor of Day 30
mortality in multivariate analysis (logistic regression, back-
ward Wald) was chronic renal failure (OR: 16.4; 95% CI:
1.3-212.5; p = 0.032) and a primary urinary tract source of
infection was associated with lower day 30 mortality
(OR: 0.042; 95% CI: 0.002-0.76; p = 0.032) (Table 2). Clonal
group O25b/ST131 was not related to Day 30 mortality in
neither univariate nor multivariate analysis. The resistance
percentage of these 60 isolates was shown on Table 3. The
PFGE result is shown in Figure 2. There were several pul-
sotypes in clonal group O25b/ST131, and one major pul-
sotype included five isolates.
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Discussion
We have shown that O25-ST131 is also the important
clone in non-ESBL-producing E. coli bacteremia. Clonal
group O25b/ST131 accounted for 5.9% in total isolates
and had a higher proportion in gentamicin, TMP/SMZ
and fluoroquinolone resistant isolates. Clonal group
O25b/ST131 existed in both multidrug-resistant and sus-
ceptible E. coli strains causing community-onset blood-
stream infection. Most cases with clonal group O25b/
ST131 did not have apparent healthcare associated risk
factors. This finding answers a previous suggestion that
the emerging of clonal group O25b/ST131 may be ex-
plained by the enhanced ability to cause extraintestinal in-
fection rather than selection by antimicrobial agents used
in hospitals. Current study excluding ESBL positive iso-
lates showed approximately one fourth of fluoroquinolone
resistant E. coli bacteremia was O25-ST131. Similar to a
previous study, although more present in multidrug-
resistant isolates, ST131 was found in both antimicrobials
susceptible and resistant blood isolates [11,12]. In a
bacteremia study in San Francisco, ST131 accounted for
approximately 20% of all drug-resistant and susceptible iso-
lates [11]. Uchida et al. investigated 219 fluoroquinolone-
resistant E. coli strains in Asian and found that 32% strains
were from the serogroup O25 [7]. In Korea, 25% of
community-onset urine E. coli isolates were ST131 from
November 2006 to August 2007 [8].
Similar to a previous study, O25-ST131 was less likely to
be associated with intra-abdominal infection and more
likely to be related to UTI [5]. In a study from Spain, some
healthcare associated risk factors such as diabetes, bedrid-
den status, and antimicrobials exposure were independent
risk factors for clone ST131 [13]. A trend for fluoroquino-
lone exposure in clonal group ST131/O25b was observed
in our study but did not reach statistical significance. How-
ever, the other correlations were not found in our series,
which is possibly explained by the fact that we included
only community-onset bacteremia, and patients with some
healthcare-associated risk factors may have been excluded.
Similar to the study in Spain, mortality was similar between
the ST131 and non-ST131 groups [13]. Our study is also
in agreement with a previous murine sepsis model in
which neither ST131 status nor fluoroquinolone resistance
Table 1 Clinical features and epidemiology data in cases
with clonal group O25b/ST131 and control group





N = 40 N = 20
Male sex 10(25) 8(40) 0.232
Age 67.0 + -13.9 66.0+/-17.7 0.807
Underlying disease
Diabetes mellitus 16(40.0) 6(30) 0.449
Hepatobiliary disease 16(40.0) 8(40) 1.000
Renal structure
abnormality
3 (7.5) 4(20) 0.208
Chronic renal disease 4(10) 4(20) 0.422
Liver cirrhosis 8(20) 2(10) 0.471
Malignancy 8(20) 7(35) 0.206








B-lactam antimicrobials 17(42.5) 6(30) 0.102
Fluoroquinolone 0(0) 2(10)
Recent operation 5(12.5) 1(5) 0.653
With Foley catheter 5(12.5) 0(0) 0.159
Infection syndrome
Urinary tract infection 22(55.0) 12(60) 0.713
Intra-abdominal infection 9(22.5) 0(0) 0.023
Outcome
Discordant antimicrobials 5(12.5) 4(20) 0.464
Shock 6(15) 4(20) 0.718
Length of stay >2 weeks 11(27.5) 6(30) 0.839
Day 30 mortality 5(12.5) 3(15) 1.000
Table 2 Univariate and multivariate analysis in risk factor
of Day 30 mortality
Parameter Univariate Multivariate
Crude OR (95% CI) Adjusted OR (95% CI)
Chronic renal disease 5.6 (3.0-31.0) 16.4 (1.3-212.5)
Urinary tract infection 0.08 (0.09-0.72) 0.042 (.002-0.76)
Malignancy 7.0 (1.4 -34.2) Not significant
Clonal group O25b/ST131 1.002 (0.99-1.013) Not significant
Table 3 Percentage of antibiotic resistance in ST 131
clones and nonST131 clones (N = 60)
Resistance percentage O25b-ST131 Non O25b-ST131 P value
(%) N = 20 N = 40
Amox/Clavu 6(30) 12(30) 0.788
TMP/SMZ 14(70) 20(50) 0.141
Ciprofloxacin 7(35) 4(10) 0.018
Cefazolin 6(30) 5(12.5) 0.099
Cefmetazole 4(20) 1(2.5) 0.038
Cefotaxime 2(10) 0(0) 0.107
Piperacillin 16(80) 26(65) 0.232
Gentamicin 11(55) 6(15) 0.001
Note: Amox/Clavu denotes as Amoxicillin/Clavunic acid, TMP/SMZ denotes
as Trimethoprim/sulfamethoxazole.
No resistance of cefepime, imipenem, amikacin found in these two groups.
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correlated with mortality [14]. More cases of clone ST131
had a higher chance of ESBL E. coli infection in the follow-
ing two years than cases of non-ST131. It remains to be
clarified if this phenomenon is related to the colonization
and transmission features of ST 131. Nevertheless, a study
from France showed that ST131 had high intestine
colonization and urinary tract infection abilities, and ac-
cording to a recent report, ST131 clone was associated
with recurrent or persistent urinary tract infection [15,16].
In our study, despite the high percentage use of dis-
cordant antimicrobials in both the ST131 and non-
ST131 groups, the mortality was not changed much.
Taking into account the predominance of ST131 in
E. coli bacteremia infection, the selection of adequate em-
pirical antimicrobials becomes difficult. In Asia, the suscep-
tibility rate to fluoroquinolones in E. coli was approximately
70% in the urinary isolates from the SMART study [17]. In
community-acquired bacteremic acute pyelonephritis, dis-
cordant empirical therapy was associated with a worse early
clinical response and longer hospital stay than in con-
cordant therapy [18-20]. However, choosing broad-
spectrum antimicrobials such as carbapenem in this
type of community-onset infection raises the concern of
antimicrobials selection pressure.
This study is limited by the following factors. First, this
is a single center study in Taiwan that included a moderate
Figure 2 Pulsed-field gel electrophoresis (PFGE) of XbaI-digested genomic DNA of 23 clonal group O25b/ST131 isolates and five
isolates with ST95 and one isolate with ST59. The major pulsotype was marked. Note: 1. One case with repeated bacteremia (two isolates #)
in the same year. 2. Two isolates* were excluded from the clinical analysis due to incomplete clinical data in the medical chart.
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number of case numbers, and we do not know if the result
can be generalized to other parts of the world. Second, we
did not collect isolates from colonization or infection after
the bacteremia episode. We ignore if the ESBL isolates
cultured after infection have the same genotype as the iso-
lates collected during the non-ESBL producing E. coli
bacteremia. Third, we used the O25b PCR as a screen and
confirm by MLST to identify the clonal group O25b/
ST131, some of isolates of ST131 but O25b negative may
be missed in this screening method. The clinical signifi-
cance of clone O25b negative ST131 was not known.
Conclusion
Our preliminary study shows that clone O25b-ST131
isolates emerged as an important cause of non-ESBL-
producing E. coli bacteremia in Taiwan. Clonal group
O25b/ST131 existed in both multidrug-resistant and sus-
ceptible E. coli strains causing community-onset blood-
stream infection. Although O25b/ST131 does not lead to a
higher mortality than other isolates, choosing an appropri-
ate antimicrobials in the empirical therapy of community-
onset E. coli bacteremia has become more challenging due
to the appearance of the ST131 clone.
Additional file
Additional file 1: Table S1. Percentage of antibiotic resistance in ST
131 clones and non ST131 clones in all isolates (N=371).
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